Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.

@article{You2014PharmacogeneticguidedSO,
  title={Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.},
  author={Joyce H S You},
  journal={Pharmacogenetics and genomics},
  year={2014},
  volume={24 1},
  pages={6-14}
}
OBJECTIVES To compare clinical and economic outcomes of two anticoagulation therapy strategies, (i) pharmacogenetic-guided selection (PG-AC) of warfarin versus novel oral anticoagulants (NOACs), and (ii) usual anticoagulation care (usual AC) in patients with atrial fibrillation (AF), from the perspective of US healthcare payers. METHODS A Markov model was… CONTINUE READING